thorac endovascular aortic repair tevar has becom attract altern treatment option mani patient specif thorac aortic diseas new devic advanc imageguid procedur continu expand indic improv neurolog outcom hemodynam manag patient critic aspect reduc neurolog deficit differ compar patient undergo open thorac aortic oper there two differ phase blood pressur manag patient thorac aortic diseas befor dure critic step tevar antiimpuls therapi facilit safe posit stent deploy after stent graft deploy control hypertens blood pressur level achiev avoid spinal cord ischemia this precis blood pressur strategi essenti ensur safe procedur good longterm result

Anja Muehle

Isil Uzun

Ziba Jalali

Ali Khoynezhad

Perioperative Hemodynamic Management and Pharmacotherapeutics of Patients Undergoing Thoracic Endovascular Aortic Repair

sinc introduct 1973 inferior vena cava filter have evolv concurr advanc technolog therefor use has expand due broader indic insert this paper focus challeng futur direct trend includ closer look complic retriev rate costeffect

Misaki M. Kiguchi

Ellen D. Dillavou

IVC Filters: Challenges and Future Directions

introduct defici vitamin through util warfarin may result increas vascular calcif complic this studi aim determin impact warfarin administr patient end stage renal diseas esrd larg nation sampl method retrospect analysi use 20052010 nation inpatient sampl nis part health care utiliz project hcup complet use icd9 diagnosi code captur patient esrd prescrib prescrib warfarin statist analysi through anova chisquar test result from 20052010 927814 patient esrd were identifi nation 35 32737 were prescrib warfarin patient prescrib warfarin had averag age 64 year 51 were male for everi comorbid condit amput congest heart failur chronic obstruct pulmonari disord cerebrovascular accid diabet hypertens myocardi infarct peripher vascular diases valvular diseas patient prescrib warfarin had signific higher rate diseas compar nonwarfarin esrd counterpart esrd patient prescrib warfarin had signific shorter length stay increas hospit charg they were more like discharg home had signific decreas inhospit mortal conclus patient esrd take warfarin more like have comorbid complic have decreas los inhospit mortal compar esrd counterpart administ warfarin

Anahita Dua

Sapan S. Desai

Harvey J. Woehlck

Cheong J. Lee

The Impact of Warfarin on Patients with End Stage Renal Disease

vascular age featur endotheli dysfunct larg arteri stiffen major risk factor develop cardiovascular diseas cvd women vascular age appear acceler dure menopaus transit particular around late perimenopaus period presum relat declin ovarian function estrogen level the mechan under endotheli dysfunct larg arteri stiffen menopaus transit complet understood oxidat stress proinflammatori cytokin tumor necrosi factor contribut endotheli dysfunct larg arteri stiffen estrogendefici postmenopaus women habitu endur exercis attenu agerel increas larg arteri stiff estrogendefici postmenopaus women can revers arteri stiffen premenopaus level estrogenreplet postmenopaus women contrast estrogen status appear play key permiss role adapt respons endothelium habitu endur exercis endotheli improv absent estrogendefici women present estrogenreplet women review here current state knowledg biolog defect under vascular age across menopaus transit particular focus potenti mechan role habitu exercis preserv vascular health key area futur research

Kerrie L. Moreau

Kerry L. Hildreth

Vascular Aging across the Menopause Transition in Healthy Women

phospholipas 2 enzym pla 2 catalyz hydrolysi glycerophospholipid sn2 posit releas free fatti acid lysophospholipid mammalian pla 2 classifi sever categori which import group includ secret pla 2 spla 2 cytosol pla 2 cpla 2 calciumdepend catalyt activ calciumindepend cytosol pla 2 ipla 2 plateletactiv factor acetylhydrolas pafahs lysosom pla 2 adiposespecif pla 2 also belong class pla 2 gener cpla 2 enzym believ play major role metabol arachidon acid ipla 2 famili membran homeostasi energi metabol spla 2 famili various biolog process the focus review recent research develop spla 2 field spla 2 secret enzym low molecular weight except giii spla 2 2 requir enzym hisasp catalyt dyad ten enzymat activ spla 2 one devoid enzymat activ have been identifi mammal some spla 2 potent arachidon acid releas from cellular phospholipid biosynthesi eicosanoid especi dure inflamm individu spla 2 enzym exhibit uniqu tissu cellular local specif enzymat properti suggest distinct biolog role recent studi indic spla 2 involv divers pathophysiolog function most part act nonredund

Preetha Shridas

Nancy R. Webb

Diverse Functions of Secretory Phospholipases A<sub>2</sub>

intact cognit function best predictor qualiti life function abil older age thus prevent cognit declin central ani effort guarante success age our grow popul elder the purpos work discuss outlook paper bridg knowledg from basic clinic neurosci aim improv how understand predict treat age diseaserel cognit impair over past six year our research team has focus intermedi neuroimag phenotyp brain vulner midlif isol under physiolog mechan the ultim goal work pave road develop earli intervent enhanc cognit function preserv brain integr throughout lifespan

Andreana P. Haley

Vascular Functions and Brain Integrity in Midlife: Effects of Obesity and Metabolic Syndrome

About this journal

Journal profile

Meet the editorial board

Editor spotlight

Find out more

This journal's articles appear in a wide range of abstracting and indexing databases, and are covered by numerous other services that aid discovery and access. Find out more about where and how the content of this journal is available.

Abstracting and Indexing

Advances in Vascular Medicine

Advances in Vascular Medicine